Logo

    michael frank

    Explore " michael frank" with insightful episodes like "The future of language learning", "Michael Frank - Einhundert Samstage", "Michael Frank on the Race to Fight Infectious Diseases | #HashtagFinance" and "One Guest: Michael Frank" from podcasts like ""The Future of Everything", "WDR 2 Lesen", "The Exchange for Entrepreneurs™ Podcast" and "One Guest"" and more!

    Episodes (4)

    The future of language learning

    The future of language learning

    Cognitive scientist Michael Frank studies differences in how children and AI learn language. There is a “data gap” between the billions of words ChatGPT has to work with and the millions of words a toddler is exposed to. But, says Frank, children learn in a rich social context that supports their learning. He’s currently conducting the “BabyView Study,” where he puts cameras on young children's heads to help him understand their learning experience, as Frank tells host Russ Altman on this episode of Stanford Engineering’s The Future of Everything podcast.

    Episode Reference Links:

    Connect With Us:

    Chapters:

    (00:00) Introduction

    Russ Altman, host, introduces the episode's focus on the future of language learning and guest, Michael Frank, an expert on how children acquire language

    (02:05) Child Vs AI Language Acquisition

    Child language acquisition and the comparison with AI systems like ChatGPT, the differences in language learning between humans and AI, including the vast data exposure AI systems have compared to children.

    (05:23) Data-driven Approaches

    The importance of big data in understanding language acquisition and the Wordbank database.

    (08:04) The Early Stages of Language Learning

    The universal aspects of language learning across different languages and cultures, specifically babbling and its evolution into language-specific sounds.

    (10:30) Exploring Multimodal Language Learning

    Introduction to the SAYcam project, and the BabyView study both using camera footage from children to gather multimodal information. 

    (13:12) Social Learning and Language Acquisition

    Insights into how social interactions and grounded contexts facilitate children's language learning. Exploration of active learning strategies in children.

    (18:22) The ManyBabies Project

    A Global research consortium to understand child development across cultures, their first study documented infants' global preference for infant-directed speech. Michael outlines the funding challenges

    (21:28) Understanding Pragmatics and AI Common Sense

    Explanation of pragmatics in language acquisition and its importance in social cognition and inference making. The connection between pragmatic language skills in children and the challenge of instilling common sense in AI systems.

    (24:21) The Role of Reading in Language Learning

    The benefits of reading to children for language development while still recognizing diverse learning paths and early auditory learning.

    (27:54) Multilingualism and Early Learning Flexibility

    The natural ease of learning multiple languages in childhood  and when and why the flexibility in language learning begins to decline.

    (30:35) Conclusion

    Connect With Us:

    Episode Transcripts >>> The Future of Everything Website

    Connect with Russ >>> Threads or Twitter/X

    Connect with School of Engineering >>> Twitter/X

    Michael Frank on the Race to Fight Infectious Diseases | #HashtagFinance

    Michael Frank on the Race to Fight Infectious Diseases | #HashtagFinance

    CSE's Barrington Miller chats with Michael Frank, CEO of Revive Therapeutics Ltd. (CSE:RVV) about his company's ambitions to enter Phase 3 clinical trial protocol to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

    Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19.

    With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury
    from organ transplantation.

    Related links
    https://revivethera.com/
    https://thecse.com/en/listings/life-sciences/revive-therapeutics-ltd

    🔴 Subscribe for more great CSE insights and interviews here: https://go.thecse.com/CSETV-Subscribe

    #alwaysinvested

    STAY CONNECTED WITH THE CSE
    =============================

    📧 - NEWSLETTER: https://go.thecse.com/CSE-Mailing-List-Subscribe
    🎧 - PODCAST: https://blog.thecse.com/cse-podcasts/
    📸 - INSTAGRAM: https://www.instagram.com/canadianexchange/
    🤝 - LINKEDIN: https://ca.linkedin.com/company/canadian-securities-exchange
    👥 - FACEBOOK: https://www.facebook.com/CanadianSecuritiesExchange/
    🐦 - X: https://x.com/CSE_News
    📝 - BLOG: https://blog.thecse.com/
    🖥 - WEBSITE: https://thecse.com/
    📖 - MAGAZINE: https://issuu.com/thecse/docs

    ©2024 CNSX Markets Inc. All rights reserved.

    Logo

    © 2024 Podcastworld. All rights reserved

    Stay up to date

    For any inquiries, please email us at hello@podcastworld.io